期刊文献+

CCR4在T_1期肺腺癌组织中的表达及其临床意义 被引量:2

Expression of CCR4 in T_1 stage lung adenocarcinoma and its clinical significance
在线阅读 下载PDF
导出
摘要 目的探讨T1期肺腺癌肿瘤浸润淋巴细胞(TILs)中趋化因子受体4(CCR4)的表达及临床意义。方法采用组织芯片技术和免疫组织化学技术测定185例T1期肺腺癌TILs中CCR4的表达情况,分析CCR4表达与临床病理特征及预后的关系。结果 CCR4表达于TILs的胞浆,阳性表达率为(17.8±7.3)%,并以17.8%为界值分为低表达组和高表达组。CCR4阳性表达率与年龄、性别、吸烟史无关(P>0.05),与T分期、淋巴结转移、脉管浸润和复发有关(P<0.05)。CCR4低表达组与高表达组患者的3年生存率分别为98.7%和88.1%,5年生存率分别为89.8%、88.1%,8年生存率分别为86.6%、51.6%,差异有统计学意义(P<0.05);CCR4低表达组与高表达组患者的3年无复发生存率分别为93.3%、82.3%,5年无复发生存率分别为86.4%、74.5%,8年无复发生存率分别为83.4%、50.5%,差异有统计学意义(P<0.05)。结论 CCR4在T1期肺腺癌TILs中的高表达与肺腺癌侵袭性增强及淋巴结转移有关,有望成为预测肺腺癌预后和靶向治疗的指标。 Objective To investigate the expression of CC chemokine receptor 4( CCR4) in tumor infiltrating lymphocytes( TILs) of T1 stage lung adenocarcinoma and analyze its correlation with clinicopathological characteristics and prognostic impact.Methods The expression of CCR4 in TILs was quantified by tissue microarray and immunohistochemistry in 185 T1 stage adenocarcinomas. The relationship between the expression of CCR4 in TILs with clinicopathological characteristics and prognosis was analyzed.Results The expression of CCR4 was located in the nucleus of lymphocytes,with a positive expression ratio of( 17. 8 ± 7. 3) %. And patients were devided into high expression group and low expression group according 17. 8%. The CCR4 expression was correlated with T stage,nodal involvement,lymphovascular invasion,and relapse( P 〈 0. 05),but not with age,gender or smoking history( P 〉0. 05). The 5-year overall survival rate of CCR4 was 88. 1%,lower than that of CCR4 low expression group( 89. 8%) with statistically significant difference( P = 0. 038). The 3-year overall survival rates of CCR4 high expression group and low expression group were98. 7% and 88. 1%,the 5-year overall survival rates were 89. 8% and 88. 1%,and the 8-year overall survival rates were 86. 6% and51. 6%,with statistical significance( P 〈 0. 05); The 3-year recurrence-free survival rates of CCR4 high expression group and low expression group were 93. 3% and 82. 3%,3-year recurrence-free survival rates were 86. 4% and 74. 5%,and 8-year recurrence-free survival rates were 83. 4% and 50. 5% with statistical significance( P 〈 0. 05). Conclusion The expression of CCR4 in TILs significantly increases with the aggression of lung adenocarcinoma and lymph node metastasis,indicating that it may be a predictor of prognosis and therapeutic target in patients with lung adenocarcinoma.
出处 《临床肿瘤学杂志》 CAS 2014年第12期1081-1085,共5页 Chinese Clinical Oncology
基金 国家外国专家局出国培训项目资助项目(20130396) 国家临床重点专科建设项目资助项目(2011873)
关键词 趋化因子受体4 肺腺癌 组织芯片 预后 CC chemokine receptor 4(CCR4) Lung adenocarcinoma Tissue microarray Prognosis
  • 相关文献

参考文献14

  • 1Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014, 511(7511) :543-550.
  • 2A1-Banna NA, Vaci M, Slauenwhite D, et al. CCR4 and CXCR3 play different roles in the migration of T cells to inflammation in skin, arthritic joints, and lymph nodes[J]. Eur J Immunol, 2014, 44(6) : 1633-1643.
  • 3Yu QM, Yu CD, Ling ZQ. Elevated circulating CD19+lympho- cytes predict survival advantage in patients with gastric cancer [J]. Asian Pac J Cancer Prev,2012,13(5) :2219-2224.
  • 4王云萱,赵红,张清媛.CXC趋化因子亚族及其受体与乳腺癌相关性的研究进展[J].临床肿瘤学杂志,2013,18(4):377-380. 被引量:6
  • 5Pease JE, Horuk R. Recent progress in the development of antag- onists to the chemokine receptors CCR3 and CCR4 [ J ]. Expert Opin Drug Discov, 2014, 9 ( 5 ) : 467-483.
  • 6贾秀杰,蔡珊.CD4+CD25+调节性T细胞在呼吸系统疾病中的作用研究[J].国际呼吸杂志,2014,34(9):701-704. 被引量:8
  • 7强光亮,郭永庆.调节性T细胞参与肿瘤免疫的研究进展[J].国际免疫学杂志,2014,37(4):280-285. 被引量:17
  • 8Li JY, Ou ZL, Yu SJ, et al. The chemokine receptor CCR4 pro- motes tumor growth and lung metastasis in breast cancer [ J ]. Breast Cancer Res Treat, 2012, 131 ( 3 ) : 837- 848.
  • 9隋军,任艳鑫,李晓江,宋鑫,马静,高伟.鼻咽癌患者中CD4^+CD25^+T细胞与CCR4的相关性[J].西安交通大学学报(医学版),2009,30(6):746-750. 被引量:7
  • 10Menetrier-Caux C, Curiel T, Faget J, et al. Targeting regulatory T cells[J]. Target Oncol, 2012, 7( 1 ) : 15-28.

二级参考文献66

  • 1PRADO-GARCIA H, AVILA-MORENO F, LOPEZ-GONZALEZ JS. Cytotoxic T lymphocytes in cancer and autoimmunity [J]. Rev Invest Clin, 2004, 56(5):629-639.
  • 2BRIVIO F, FUMAGALLI L, PAROLINi D, et al. T-helper/ T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients [J]. In Vivo, 2008, 22(5):647-650.
  • 3LIYANAGE UK, MOORE TT, JOO HG, et al. Prevalence of regulatory T ceils is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma [J]. J Immunol, 2002, 169(5):2756-2761.
  • 4ORMANDY LA, HILLEMANN T, WEDEMEYER H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma [J]. Cancer Res, 2005, 65(6) :2457-2464.
  • 5WOO EY, CHU CS, GOLETZ TJ, et al. Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage nonsmall cell lung cancer and late-stage ovarian cancer [J]. Cancer Res, 2001, 61(12):4766-4772.
  • 6YANG ZZ, NOVAK A J, STENSON MJ, et al. Intratumoral CD4^+CD25^+ regulatory T-cell-mediated suppression of infiltrating CD4^+ T cells in B-cell non-Hodgkin lymphoma [J]. Blood, 2006, 107(9) :3639-3646.
  • 7VIGUIER M, LEMA TRE F, VEROLA O, et al. Foxp3 expressing CD4^+ CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells [J]. J Immunol, 2004, 15; 173 (2) : 1444-1453.
  • 8LAU KM, CHENG SH, LO KW, et al. Increase in circulating Foxp3^+ CD4^+ CD25 (high) regulatory T cells in nasopharyngeal carcinoma patients [J]. Br J Cancer, 2007, 96(4):617-622.
  • 9GIATROMANOLAKI A, BATES GJ, KOUKOURAKIS MI, et al. The presence of tumor-infiltrating FOXP3^+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer [J]. Gynecol Oncol, 2008, 110(2) :216-221.
  • 10KERSHAW MH, WANG G, WESTWOOD JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2 [J]. Hum Gene Ther, 2002, 13(16): 1971-1980.

共引文献34

同被引文献14

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics [ J]. CA- Cancer J Clin, 2013, 63(1):11-30.
  • 2Liu H, Lv Z, Guo E. Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition [ J ]. Int J Clin Exp Pathol, 2015, 8(8) :9140-9146.
  • 3Chen S, Shao C, Xu M, et al. Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-codin- gRNA UCA1 [J]. Int J Clin Exp Pathol, 2015, 8(8) :9052 -9061.
  • 4Xiao H, Yuan Z, Guo D, et al. Genome-wide identification of long noncoding RNA genes and their potential association with fe- cundity and virulence in rice brown planthopper, Nilaparvata lu- gens[J]. BMC Genomics, 2015, 16(1) :749.
  • 5Dang Y, Lan F, Ouyang X, et al. Expression and clinical signifi- cance of long non-coding RNA HNF1A-AS1 in human gastric cancer[J]. World J Surg Oncol, 2015, 13:302.
  • 6Yao J, Chen Y, Wang Y, et al. Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas [ J ]. Int J Clin Exp Pathol, 2014, 7(6) :2758-2767.
  • 7Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: A new frontier of translational research? [ J ]. Oncogenc, 2012, 31 ( 43 ) : 4577- 4787.
  • 8Huarte M, Rinn JL. Large non-coding RNAs: Missing links in cancer? [J]. Hum Mol Genet, 2010, 19(2) : 152-161.
  • 9Naemura M, Murasaki C, Inoue Y, et al. Long noncoding RNA ANRIL regulates proliferation of non-small cell lung cancer and cervical cancer ceils [ J ]. Anticancer Res, 2015, 35 (10) : 5377 -5382.
  • 10Wu J, Zhang J, Shen B, et al. Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition [ J ]. J Exp Clin Cancer Res, 2015, 34 ( 1 ) : 116.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部